Psychiatry

A genome-wide study of > 460,000 individuals identify 27 loci separating AERS+ and AERS− subtypes of major depressive disorder by metabolic profile.

Resilient Pharmaceuticals has resubmitted its MDMA-assisted therapy NDA for PTSD without a new phase 3 trial, MAPS reported.

Merve Karaca Şahin, MD, discusses fear- and picky-eating-driven ARFID behaviors in children with food allergy.

Centanafadine FDA approval, DT120 EMERGE trial results, and COMP360 psilocybin data headline this month's psychiatry coverage.

The first-in-class NDSRI showed significant symptom improvement as early as week 1 across 4 phase 3 trials but carries boxed warnings for suicidality and abuse potential.

John Sonnenberg, PhD, outlines EMERGE trial criteria, dosing sessions, and endpoints for DT120 (lysergide) ODT 100 µg in major depressive disorder.

Boadie Dunlop, MD, discusses COMP360 dosing-day monitoring, treatment resistance, and where psilocybin may fit among existing TRD options.

This week’s headlines include the FDA acceptance of mitapivat and roflumilast applications, the approval of atacicept for IgA nephropathy, and more.

New Phase 3 COMP006 data show durable MADRS improvement in treatment-resistant depression following two doses of synthetic psilocybin.

First half 2026 psychiatry recap: Lumateperone and milsaperidone approvals, ProlivRx for MDD, centanafadine for ADHD, and 3 psychedelic trials.

Q2 2026 psychiatry recap: Lumateperone expands for schizophrenia relapse, DT120 shows phase 3 promise in MDD, and 3 TMS advances for depression care.

From an ADHD therapy's regulatory setback to a psychedelic's rapid MDD response and TMS's move into patients' homes, here are 3 psychiatry stories from June 2026 you may have missed.

A review of 22 novel drugs approved by the US Food and Drug Administration during the first half of 2026, with links to coverage from MJH Life Sciences publications.

Stay updated with the latest healthcare breakthroughs, including FDA regulatory decisions, phase 3 data, and new clinical guidelines.

From FDA-approved at-home TMS and accelerated protocols to conversational AI matching group therapy outcomes, here are 5 psychiatry updates from May every clinician should know.

The FDA declined to approve Cingulate's once-daily ADHD therapy CTx-1301, citing CMC information requests with no clinical safety or efficacy concerns identified.

Transcranial magnetic stimulation for major depressive disorder is shifting toward accelerated (5x5 and SWIFT protocol) and at-home models (ProlivRx).

In a Q&A, psychiatrist Scott Wilke, MD, explains how accelerated TMS protocols are reshaping depression care and may help tailor treatment to specific neural circuits.

A study suggested lumateperone demonstrated favorable efficacy outcomes and limited weight gain and akathisia risk compared with other adjunctive antipsychotics for MDD.

Perez discusses the next steps before a marker like monocyte epigenetic age acceleration could be considered clinically actionable for precision psychiatry in depression.

Interview with Perez on how monocyte-derived epigenetic clocks outperform multi-tissue models in detecting symptom-specific depression signals.

Routine depression and anxiety screening in IBD clinics was tied to significantly more referrals and sustained follow-up with psychogastroenterology services

In this interview, Perez discusses data linking monocyte epigenetic age acceleration to non-somatic depressive symptoms.

Shoshani discusses RCT data showing AI reduces anxiety and improves well-being, with outcomes comparable to those of group therapy.

Without FDA-approved medications or standardized detox protocols, clinicians face unique challenges treating methamphetamine addiction.